LOPRAZOLAM MESILATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H21ClN6O3.CH4O3S
Molecular Weight	561.01
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN1CCN(CC1)\C=C2/N=C3CN=C(C4=CC=CC=C4Cl)C5=C(C=CC(=C5)[N+]([O-])=O)N3C2=O

InChI

InChIKey=DDSDPQHQLNAGLJ-YEBWQKSTSA-N

InChI=1S/C23H21ClN6O3.CH4O3S/c1-27-8-10-28(11-9-27)14-19-23(31)29-20-7-6-15(30(32)33)12-17(20)22(25-13-21(29)26-19)16-4-2-3-5-18(16)24;1-5(2,3)4/h2-7,12,14H,8-11,13H2,1H3;1H3,(H,2,3,4)/b19-14-;

HIDE SMILES / InChI

Molecular Formula	C23H21ClN6O3
Molecular Weight	464.904
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con418469.pdf
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/hmr/dormnoct.html

Loprazolam is a hypnotic drug which stimulates GABA-A receptors. Due to its hypnotic activity the drug is used to treat short-term sleep disordes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con418469.pdf	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Short term slep problems 3 Sources: http://home.intekom.com/pharm/hmr/dormnoct.html	Primary		Approved 8583	DORMONOCT Approved Use Short-term treatment of insomnia.Sleep disturbances in the geriatric patient. Pre-operative sleep disturbances.

C_max

Value	Dose	Analyte	Population
4.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
46.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
74.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
35.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
50 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
11.22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LOPRAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LOPRAZOLAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
15% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6140793/			LOPRAZOLAM plasma	Homo sapiens

Doses

Dose	Population	Adverse events
1 mg 7 times / day multiple, oral Recommended Dose: 1 mg, 7 times / day Route: oral Route: multiple Dose: 1 mg, 7 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6147285/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6147285/	Sources: https://pubmed.ncbi.nlm.nih.gov/6147285/
2 mg single, oral Recommended Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/	Other AEs: Lethargy, Dizziness... Other AEs: Lethargy Dizziness (20%) Ataxia (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/

AEs

AE	Significance	Dose	Population
Lethargy		2 mg single, oral Recommended Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/
Ataxia	20%	2 mg single, oral Recommended Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/
Dizziness	20%	2 mg single, oral Recommended Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6132929/

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dose is 1 - 2 mg at bedtime.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:17:21 GMT 2025` Edited by `admin` on `Mon Mar 31 19:17:21 GMT 2025`
Record UNII	VKF8383J65
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LOPRAZOLAM METHANESULFONATE

Preferred Name

English

LOPRAZOLAM MESILATE

Common Name

English

Loprazolam mesilate [WHO-DD]

Common Name

English

RU-31158

Code

English

SOMNOVIT

Brand Name

English

1H-IMIDAZO(1,2-A)(1,4)BENZODIAZEPIN-1-ONE, 6-(2-CHLOROPHENYL)-2,4-DIHYDRO-2-((4-METHYL-1-PIPERAZINYL)METHYLENE)-8-NITRO-, (2Z)-, METHANESULFONATE (1:1)

Systematic Name

English

SONIN

Brand Name

English

LOPRAZOLAM MESILATE [MART.]

Common Name

English

LOPRAZOLAM METHANESULFONATE [MI]

Common Name

English

HR-158

Code

English

LOPRAZOLAM MESYLATE

Common Name

English

DORMONOCT

Brand Name

English

HAVLANE

Brand Name

English

Code System Code Type Description

CAS

70111-54-5